Unpacking Healthcare With Sector Specialist Mike Perrone, CFA - Compound Insights Recap

Podcast: Compound Insights

Published: 2026-02-03

Duration: 29 min

Summary

Mike Perrone discusses the recent recovery of the biopharma sector and the investment opportunities that lie within healthcare, particularly focusing on health insurers and advancements in AI-driven diagnostics.

What Happened

In this episode, host Gary Farber interviews Mike Perrone, a healthcare specialist at Baird, who shares insights on the healthcare sector's recent performance and future prospects. One of the most notable surprises in 2025 was the positive turn in the sector following the first favored nation deal between the White House and Pfizer. This deal, which did not impose significant price cuts, alleviated fears around drug pricing pressure, allowing companies to regain confidence and increase spending. Perrone notes that this 'debt clearing event' has led to a rally in healthcare stocks, particularly within the biopharma sector, which had been struggling post-COVID due to scrutiny and headwinds in the market.

Looking ahead, Perrone highlights key investment themes for 2026, suggesting that the biopharma recovery is gaining momentum. He anticipates continued improvement in pharma spending as companies no longer fear pricing cuts. Moreover, he points out that the health insurers' sector presents an interesting opportunity due to low valuations and potential margin recovery despite recent pressures from government rate notices. Perrone emphasizes the cyclical nature of this sector and the likelihood of a re-rating cycle in the coming years, making it a value-oriented area for investors to watch closely.

Key Insights

• The healthcare sector, particularly biopharma, is experiencing a recovery driven by reduced fears of drug pricing cuts.
• Health insurers are undervalued and may see a margin recovery despite current pressures.
• AI is increasingly influencing drug discovery and diagnostics, enhancing efficiency and accuracy in healthcare.
• M&A activity is expected to be pervasive in the healthcare sector as companies look to innovate and expand.

Key Questions Answered

What were the surprises in the healthcare sector in 2025?

Mike Perrone notes that a significant surprise was the positive turn in the healthcare sector following the favored nation deal between the White House and Pfizer. This deal did not involve serious price cuts, which alleviated fears regarding drug pricing pressure. The healthcare sector had been under scrutiny for years and struggled post-COVID, but this deal cleared the way for increased confidence and spending in the biopharma sector, leading to a rally in healthcare stocks.

What investment themes are emerging for 2026 in healthcare?

Perrone identifies that the biopharma sector's recovery is likely to continue into 2026, as companies are expected to spend more freely due to lower fears about drug pricing cuts. He highlights that capital markets are opening up again, and there's a renewed interest in biopharma driven by M&A and innovation. Additionally, he points out that health insurers present a compelling investment opportunity due to low valuations and the cyclical nature of the industry, despite facing some margin pressures.

How is AI impacting the healthcare sector?

AI is playing a significant role in improving efficiency within the healthcare sector, particularly in drug discovery and diagnostics. Perrone mentions how companies are utilizing AI for bias simulation and virtual clinical trials, which enhances the drug development process. Additionally, the use of AI in diagnostics, such as liquid biopsies for cancer screening, showcases how technology can improve early detection and patient outcomes by analyzing minute amounts of tumor presence in blood samples.

What challenges do health insurers face currently?

Health insurers are currently facing challenges related to margin compression due to increased utilization in 2025. Perrone explains that while insurers typically manage to reprice and rebalance after such periods, the recent Medicare advantage rate notices from the government did not meet expectations. This has led to further margin pressure and a significant reset in stock valuations, making it a critical time for investors to monitor this sector closely.

What role will M&A play in the healthcare sector going forward?

M&A activity is anticipated to be a significant theme in the healthcare sector as companies seek to innovate and expand their capabilities. Perrone suggests that as the biopharma sector recovers, there will be increased merger and acquisition activity, which can create further opportunities for growth and investment. The dynamic nature of the healthcare landscape, coupled with advancements in technology and regulatory changes, will likely drive this trend in the coming years.